Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 3:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Togaviridae Infections Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers

NCT00384397
View directory record Official record
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
249 Days to 305 Days
Enrollment
1,128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
39
States / cities
Montgomery, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Jul 24, 2026, 3:34 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.

NCT07003984
View directory record Official record
Conditions
Chikungunya Virus
Interventions
CHIKV VLP vaccine, Placebo
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
1 Year to 11 Years
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
8
States / cities
Fountain Valley, California • Washington D.C., District of Columbia • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jul 24, 2026, 3:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults

NCT03829384
View directory record Official record
Conditions
Prevention of Chikungunya Virus Infection
Interventions
mRNA-1944, Placebo
Biological · Other
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Jul 24, 2026, 3:34 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

300 Antibody Diagnostic Test Kit

NCT01646411
View directory record Official record
Conditions
Acute Bacterial Infections, Acute Viral Infections
Interventions
Not listed
Lead sponsor
The Plasma Source
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Southampton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Jul 24, 2026, 3:34 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers

NCT00626327
View directory record Official record
Conditions
Meningococcal Infections
Interventions
MenACWY-CRM + MMRV, MMRV, MenACWY-CRM
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
7 Months to 1 Year
Enrollment
1,630 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
90
States / cities
Birmingham, Alabama • Dothan, Alabama • Greenville, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2013 · Synced Jul 24, 2026, 3:34 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis (VEE) Vaccine as Booster Vaccine in Adults

NCT03531242
View directory record Official record
Conditions
Venezuelan Equine Encephalomyelitis
Interventions
0.5 mL Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Fort Deterick, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Jul 24, 2026, 3:34 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

NCT04546724
View directory record Official record
Conditions
Chikungunya Virus Infection
Interventions
VLA1553, Placebo
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
18 Years and older
Enrollment
4,128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
44
States / cities
Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Jul 24, 2026, 3:34 AM EDT
Enrolling by invitation No phase listed Observational

Xpert® Tropical Fever Test on GeneXpert® Edge X System

NCT07520279
View directory record Official record
Conditions
Malaria Fever, Zika, Dengue Fever, Leptospirosis, Chikungunya Virus Infection
Interventions
Xpert Tropical Fever test
Diagnostic Test
Lead sponsor
Cepheid
Industry
Eligibility
14 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 24, 2026, 3:34 AM EDT
Completed No phase listed Observational

Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)

NCT02794181
View directory record Official record
Conditions
Zika Virus, Dengue Virus, Chikungunya Virus Infections
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2019 · Synced Jul 24, 2026, 3:34 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years

NCT05349617
View directory record Official record
Conditions
Chikungunya Virus
Interventions
CHIKV VLP/adjuvant, Placebo
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
65 Years and older
Enrollment
413 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
10
States / cities
Miami, Florida • Miami Lakes, Florida • St. Petersburg, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Jul 24, 2026, 3:34 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study Evaluating the Safety, Tolerability, and Immunogenicity of V4020 Vaccine in Healthy Volunteers

NCT07088822
View directory record Official record
Conditions
Venezuelan Equine Encephalitis, Venezuelan Equine Encephalitis Virus Infection
Interventions
V4020
Biological
Lead sponsor
Medigen, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Jul 24, 2026, 3:34 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults

NCT04786444
View directory record Official record
Conditions
Chikungunya Virus Infection
Interventions
Biological Vaccine VLA1553
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
18 Years to 45 Years
Enrollment
409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
12
States / cities
Coral Gables, Florida • Fort Myers, Florida • Ponte Vedra, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Jul 24, 2026, 3:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects

NCT04131595
View directory record Official record
Conditions
Equine Encephalitis
Interventions
MVA-BN-WEV Dose 1, MVA-BN-WEV Dose 2, MVA-BN-WEV Dose 3
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Jul 24, 2026, 3:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)

NCT03992872
View directory record Official record
Conditions
Chikungunya
Interventions
Chikungunya
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Fort Deterick, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Jul 24, 2026, 3:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age

NCT05630846
View directory record Official record
Conditions
Measles; Mumps; Rubella; Chickenpox, Measles
Interventions
Investigational MMRV(H)NS vaccine, Investigational MM(H)RVNS vaccine, Investigational M(L)M(L)R(L)V(L)NS vaccine, Marketed MMRV_Lot 1 and Lot 2 vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 6 Years
Enrollment
801 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
35
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Bellflower, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Jul 24, 2026, 3:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Study of SAR440894 vs Placebo

NCT04441905
View directory record Official record
Conditions
Chikungunya Virus Infection
Interventions
Placebo, SAR440894
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
3
States / cities
Orlando, Florida • Durham, North Carolina • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jul 24, 2026, 3:34 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)

NCT05072080
View directory record Official record
Conditions
Chikungunya Virus
Interventions
CHIKV VLP/adjuvant, Placebo
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
12 Years to 64 Years
Enrollment
3,258 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
47
States / cities
Huntsville, Alabama • Mobile, Alabama • Tempe, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Jul 24, 2026, 3:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine

NCT02654509
View directory record Official record
Conditions
Eastern Equine Encephalitis
Interventions
Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2018
U.S. locations
1
States / cities
Fort Deterick, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Jul 24, 2026, 3:34 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination

NCT06007183
View directory record Official record
Conditions
Chikungunya Virus Infection
Interventions
CHIKV VLP vaccine booster, Placebo booster
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
12 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
24
States / cities
Mobile, Alabama • Tempe, Arizona • Melbourne, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Jul 24, 2026, 3:34 AM EDT
Recruiting Phase 4 Interventional

Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients

NCT07195032
View directory record Official record
Conditions
Heart Transplant Infection Prevention
Interventions
Commercial measles, mumps, and rubella (MMR) vaccine
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
1 Year to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Jul 24, 2026, 3:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age

NCT00861744
View directory record Official record
Conditions
Rubella, Mumps, Measles, Measles-Mumps-Rubella Vaccine
Interventions
GSK Biological's investigational vaccine 209762, M-M-R® II (Merck and Co), Varivax®, Havrix®, Prevnar®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
1,259 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
45
States / cities
Tuscaloosa, Alabama • Conway, Arkansas • Jonesboro, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Jul 24, 2026, 3:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Trial of Measles Vectored Chikungungya Vaccine

NCT03028441
View directory record Official record
Conditions
Chikungunya Virus Infection
Interventions
Placebo, VRC-CHKVLP059-00-VP
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
3
States / cities
Atlanta, Georgia • Iowa City, Iowa • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced Jul 24, 2026, 3:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Defining Skin Immunity of a Bite of Key Insect Vectors in Humans

NCT03641339
View directory record Official record
Conditions
Zika, Dengue, Malaria, Chikungunya, Leishmaniasis
Interventions
One vector feeding, Four vector feeding
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Jul 24, 2026, 3:34 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

NCT02184572
View directory record Official record
Conditions
Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine
Interventions
Priorix, M-M-R II, Varivax, Havrix, Prevnar 13
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
1,742 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
80
States / cities
Birmingham, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 69 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Jul 24, 2026, 3:34 AM EDT